The scrip slipped to a low of Rs 950 and finally ended at Rs 952, down around 4% from the previous close. The counter clocked volumes of 116,392 shares on the BSE
______________________________________________________
(Updated at 1050hrs)
Dr Reddy's has shed in early trades following a recall of four of its drugs from US.
The stock opened at Rs 982 and touched a high of Rs 983. However, it slipped 3.5% to touch a low of Rs 955. The stock is now down over 2% at Rs 966. However the stock has gained 23% in the past month. Around 38,076 shares have been traded on the BSE so far.
Dr Reddy's has recalled four products from its key US market. The products were recalled because of oversized capsules. The capsules are used to treat major depression associated with mood disorders and anxiety, for hay fever and allergies, for lowering cholesterol and preventing cardiovascular disease and for treating schizophrenia.
The US accounts for 35% of Dr Reddy's turnover of close to Rs 6,945 crore, which includes active pharmaceutical ingredient sales.
Yesterday, in intraday trades the stock had tumbled 7% from its high to a low of Rs 940.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
